COVID-19 Update: Neuromuscular Research
University Hospitals Leads Clinical Research Studies Exploring Neuromuscular Diseases
Advanced research and clinical trials are a key component of the Neuromuscular Center’s mission at University Hospitals Neurological Institute. Our physician-researchers are involved in a variety of investigations, each with the potential to improve diagnosis and treatment. Our physicians and scientists contribute to:
- ICE PAC NIH Grant (Interstitial Cystitis Evaluation of Psychophysiologic and Autonomic Characteristics): To understand the role of the nervous system in this debilitating chronic pain disorder, as well as in another pelvic pain disorder called myofascial pelvic pain syndrome.
- MUSK Study for patients with myasthenia gravis
-
We are currently enrolling in the MSK-002 trial (“A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients”). This is a study for patients with a condition called myasthenia gravis, specifically those who are not getting effective benefit or are not tolerating their medication for the disease. The purpose of the study is to learn about the safety and effectiveness of a drug called amifampridine phosphate. This drug has not been approved by the U.S. FDA, but it has been approved to treat an autoimmune disorder in the European Union.
You may qualify for this study if:
- You are 18 years of age or older
- You have a documented and confirmed diagnosis of myasthenia gravis
- You are not taking certain medicines that might interfere with the study drug or procedures
- Your doses of certain medications are stable and will not interfere with study drug or procedures
**(Your medications will be reviewed by the study doctor and study team to confirm safety and eligibility)
- ALXN-1210-MG-306 trial for patients with generalized Myasthenia Gravis (gMG)
-
We are currently enrolling in the ALXN-1210-MG-306 trial (A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis). The study is looking at the safety and effectiveness of an experimental drug, intravenous ravulizumab, compared to placebo, in patients with gMG. About 160 patients will be enrolled in the trial around the world. Your participation in this study will last for about 132 weeks. Risks, benefits, and further information about study participation can be discussed with a study coordinator and the investigators on the trial.
You may qualify if:
- You are at least 18 years of age
- You have been diagnosed with MG in the past 6 months
- You are on a stable dose of other MG medications
- You have not had a thymectomy in the past 12 months
- ADVANCE-CIDP™ 1 Study for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
-
We are currently enrolling in the ADVANCE-CIDP™ 1 trial (Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP). The study is aiming to find out whether a potential new treatment (an investigational medication) could help to prevent muscle weakness of the upper and lower limbs, compared to placebo, in patients with CIDP. About 232 patients will be enrolled in this study around the world. Your participation in this study will last for about 27 weeks. Risks, benefits, and further information about study participation can be discussed with a study coordinator and the investigators on the trial.
You may qualify if:
- You are at least 18 years of age
- You have been diagnosed with CIDP
- You have been receiving treatment with immunoglobulin infusions at a stable dose, every 2–6 weeks, for at least 12 weeks (about 3 months)For more information about the study or to see if you may be a good candidate for this trial, please click here.